HARVARD BIOSCIENCE INC

Harvard Bioscience, Inc. (NASDAQ: HBIO) is a leading developer, manufacturer, and seller of technologies, products, and services that enable fundamental advances in life science applications. The company's website is www.harvardbioscience.com.

Founded in 1901 by Dr. William T. Porter, a Professor of Physiology at Harvard Medical School, Harvard Bioscience has evolved from its origins in physiology education to become a comprehensive provider of research and drug discovery tools. The company traces its modern corporate structure to 1996 when investors acquired the predecessor business, with Harvard Bioscience, Inc. incorporated in Delaware in 2000. A significant milestone occurred in 2018 with the acquisition of Data Sciences International, Inc., which expanded the company's portfolio to address the continuum from research and discovery through preclinical testing.

The company operates through two primary product families. The Cellular and Molecular Technology (CMT) product family, representing approximately 46 percent of revenues, includes electroporation instruments, amino acid analyzers, spectrophotometers, precision pumps, and micro-electrode array solutions supporting academic research and drug discovery. The Preclinical product family, comprising approximately 54 percent of revenues, provides telemetry systems, behavioral products, respiratory systems, and data acquisition platforms for drug development and safety testing. The company also distributes complementary third-party products, accounting for approximately 13 percent of revenues.

Harvard Bioscience serves a diverse customer base including pharmaceutical and biotechnology companies, universities, government laboratories, hospitals, and contract research organizations. Major customers include Abbott, Amgen, AstraZeneca, Bayer, Johnson & Johnson, Merck, Pfizer, and Regeneron, alongside academic institutions such as Harvard University, Stanford, and Johns Hopkins University.

As of December 31, 2025, the company employed 339 people across manufacturing facilities in the United States, Germany, and Spain, with additional operations in the United Kingdom, China, and other locations. The company conducts direct sales and distribution through partners globally, with approximately 61 percent of revenues from direct sales and 39 percent through distributors. The company maintains a portfolio of 11 issued patents and 5 pending patent applications covering its proprietary technologies.